Kane Biotech Inc. announced the formation of a Scientific Advisory Board, chaired by Kane Biotech Board Director Rivka Gluck, and will work closely with senior management to advance the Company’s integration and scope of clinical applications of its patented anti-microbial technology. The SAB, comprised of experts in human health and industrial biotech will also include the appointments of Gordon Guay, Ph.D., and Robert Huizinga, Ph.D. The SAB will work closely with Kane Biotech management as it actively identifies and explores the potential of Kane’s intellectual patent portfolio to positively impact untapped applications in industrial and human health applications.